Genentech announced results of a phase 3 study to assess the value of combining Tecentriq and Avastin as a first-line treatment for advanced or metastatic renal cell carcinoma.
Results showed the combination met the coprimary endpoint of investigator-assessed, progression-free survival and demonstrated a statistically significant and clinically meaningful reduction in the risk of disease worsening or death for patients whose disease expressed the programmed death-ligand 1 protein of at least 1% compared to use of sunitinib.
“We are encouraged by these results as they add to the emerging body of evidence that supports our rationale for this combination. We believe that the regimen of Tecentriq [atezolizumab, Genentech] and Avastin [bevacizumab, Genentech] may enhance the potential of the immune system in the initial treatment of advanced kidney cancer,” Sandra Horning, MD, chief medical officer and head of Global Product Development for Genentech, said in a company press release.
Safety for the combination appeared consistent with the known safety profile of the individual medicines and what was previously reported in the phase 2 IMmotion150 study. According to the press release, no new safety signals were identified with the combination.
IMmotion151 is a phase 3 multicenter, randomized, open-label study that enrolled 915 patients globally who were randomized 1:1 to receive atezolizumab and bevacizumab or sunitinib alone. Patients in the combination treatment arm received atezolizumab at a fixed dose of 1,200 mg and bevacizumab at a dose of 15 mg/kg via IV infusion every 3 weeks until loss of clinical benefit or unacceptable toxicity. People in the sunitinib arm received 50 mg orally, once daily for 4 weeks followed by 2 weeks rest until loss of clinical benefit or unacceptable toxicity.